Emerging fund managers and founders trust our team with the experience, industry insights and domain expertise earned over time.
Our lawyers have over 10 years of experience representing operators, accelerators, and emerging fund managers in their deals. We focus solely on structuring early stage investments—including Series Seed and Series A—targeting private investment funds with less than $100M AUM.
We have a demonstrated ability to structure emerging venture capital funds and emerging growth companies to align with the risk-adjusted profiles & business philosophies of our clients.
We offer legal representation to emerging fund managers with less than $100M in AUM. Our core experience is in the early stage venture process representing venture fund managers writing checks in $250K-$5M range, pre-Seed, Seed and Series A stages.
Our unique blend of startup law and VC fund experience aligns us well with accelerators, who have capital constraints that funds typically do not. We help to automate our clients' legal forms and documents to maximize the efficiencies of our legal work product.
Fund formation means committing to an investment goal for over 10 years with a group of investors that back your vision. Emerging fund managers have a herculean task of learning the lingo, connecting the dots and understanding portfolio management. We focus on our core competency: Structuring your venture fund.
We have counseled hundreds of startups and emerging growth companies from capital formation to exit. Client representation includes VC-backed startups with a focus on post-formation, founder agreements, corporate contracts, employment matters, option plans, securities issuances and general business matters.
Harvey Esquire provides counsel on M&A transactions involving technology, life sciences, and emerging growth enterprises at the peak stage of development. The firm has experience advising both sellers and purchasers of technology and life sciences, including stock purchase agreements, asset purchase agreements, LLC purchase agreements, and statutory conversions.
Harvey Esquire provides counsel on M&A transactions involving technology, life sciences, and emerging growth enterprises at the peak stage of development. The firm has experience advising both sellers and purchasers of technology and life sciences, including stock purchase agreements, asset purchase agreements, LLC purchase agreements, and statutory conversions.
